FirstWord: Market Research Reports

... . For the Pharma industry it’s tight, and it’s getting tighter. Essential market access data and insights are now available in this new report ... , Market Access in the EU5 – a comparative overview, provides a detailed snapshot of the current environment and trends that are influencing market access in the five leading EU markets: France ...

... how gamification can influence product innovation Understand how gamification can change clinician and patient behavior Be ready for future developments. Pharma and Gamification: motivating positive outcomes – a primer answers key questions: How is the global gamification market evolving? How are pioneering Pharma companies involved in gamification? Why has Pharma ...

... GlaxoSmithKline at September's AdCom. Most pertinently, suggested analysts at JP Morgan last week, could be the AdCom's view ... a 24-hour period (see In Focus: Can Pearl Therapeutics support AstraZeneca's late ... always uniformly dispersed). This week's FirstWord Physician Views poll will ask: To what percentage ...

... run in January looking at physician detailing, this week’s FirstWord Physician Views poll investigates which companies are best at physician marketing in the diabetes space. Notably, failure to gain ... endocrinologists, which are the best detailing diabetes companies and drugs and what factors support this view. This week's FirstWord Physician Views poll will ...

... , losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the ... ) comes in. Scope Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to: Understand the landscape of biosimilar/biobetter development ...

... on China’s sales operations and tactics. FirstWord’s new report sheds light on how Pharma is using its still-expanding Chinese sales force, with exclusive insights from sales managers at multinational and domestic companies China’s economy is one ...

... to extend and enhance its market-leading Lantus franchise. At the ADA meeting, Sanofi released the first Phase III data for ... patent expiry date is feasible. In light of recent developments, this week’s Physician Views poll will ask US-based endocrinologists: Whether they anticipate data ...

... access patient input. What’s more, there is no broad consensus on patient-centric practices, nor are there standard operating procedures. That is, until now. In Patient-Centricity: Solving the latest marketing ... into how to integrate patient-centricity into the pharma business model. Scope Patient-Centricity: Solving the latest marketing puzzle answers key questions: Patient-centric efforts are moving to the ...

... for biosimilar developers and will add some incremental pressure on branded players. The key question remains, however; will physicians prescribe biosimilar Remicade once it becomes available? This week's Physician Views poll asks rheumatologists and gastroenterologists based ...

... can access results from an earlier Physician Views poll of US-based pulmonologist attitudes towards Breo The attitude of European pulmonologists towards usage of a once-daily LABA ... for Relvar in Europe. Purchase Reasons This week's Physician Views poll will specifically ask pulmonologists based in the 5EU countries: What percentage of COPD ...

... still generate blockbuster revenues based on its performance in ex-US markets, the key implication (from a commercial perspective) being how this will ... can develop similarly to the US; where Invokana has been submitted to the European Medicines Agency but has yet to be approved. This week's Physician Views ...

... unique insider input and case studies This new report, Value-based Key Account Management and the NHS — Ensuring optimal performance under new ... spend time sitting in clinics, interviewing consultants, nursing staff and departmental managers to really understand what the issues are in this setting.” Jo Wales, ...

... . This insightful report brings you completely up to date with the biosimilar competitive landscape, and gives you the information you need ... .” Warwick Smith, director-general, British Generic Manufacturers Association Biosimilar Defensive Plays - assessing the options is designed to answer your strategic and ...

... survival (Novartis is seeking to demonstrate this benefit for Tasigna versus Gleevec). However, there would appear to be a limited window of maximum commercial ... expiry in 2015. Set against this backdrop of uncertainty, this week's Physician Views poll will ask US-based oncologists to share their opinions ...

... of pharmaceutical manufacturers, this week's Physician Views poll will seek feedback from US-based endocrinologists on three key recent developments – discussion regarding pancreatic cancer/pancreatitis ... Physicians View poll will ask US-based endocrinologists: How their prescribing of DPP-4 and GLP-1 products may shift in light of the FDA’s recent assessment ...

... the company. Ensuring Optimal Medical Affairs Performance: delivering measurable value is an invaluable resource for anyone interested in the evolution, measurement, and management of Medical Affairs – including Medical Affairs directors; Brand ... to ensure that Medical Affairs staff don’t feel alienated) Be aware of the benefits of cloud computing and tablet technology Highlights Key Questions Answered Ensuring Optimal Medical Affairs Performance: delivering ...

... rethink fundamentally their drug development and marketing strategies. Everyone is a winner with companion diagnostics. ... . Patients benefit from effective treatment and reduced side effects. Payers benefit ... the new market realities and partnership working with wider stakeholder education and integrated sales ...

... RA patients. But is the market opportunity for alternative biologic RA therapies ... these questions, this week's Physician Views poll asks rheumatologists ... what scenario they think would most likely see them increasingly usage of an alternative product in favour of an anti-TNF in RA patients progressing beyond ...

... on physician communities – Digital Doctors: Marketing to Online Networks (2nd Edition) – is your definitive guide to the leading online physician networks in both developed and emerging markets: What are ... , Marketing Communications/Channels, Merck Sven Awege, pharma digital consultant (clients have included Eli Lilly and Doctors.net.uk) Tim Ringrose, CEO of Doctors.net ...

... extensive analysis from experts in many fields to predict the top 10 Pharma companies in 2017. To stay ahead of your competition, you need to have the ... fingertips. Download this powerful report today. Each of the top 10 pharma companies for 2017 has its own report, providing an overall sales ... for the ten pharma companies that are expected to lead the market in 2017 Analyst consensus sales forecasts for each company’s top five ...

... FirstWord research is provided in two comprehensive modules: The KOL Insight: HIV module provides a complete review underpinned by exclusive in-depth interviews with ... Protease inhibitors CCR5 inhibitor Expert Opinion for Real World Insights The data and analysis in the report is enriched through the ...

... Pharma do to maximise the credibility and visibility of its products? Overview The Path to Product Inclusion in Clinical Guidelines: Strategies for Success If you ... defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical

... and mHealth developers themselves. Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging ... from pharma in developing mHealth apps for healthcare providers Detailed insight into five major pharma mHealth projects Methodologies for determining the platforms on which mHealth ...

... on big data and how to work with it. Key Report Features A background to big data A summary of big data sources for pharma and biotech Uses for big data in pharma and biotech marketing Lessons from other industries Challenges facing those wanting to use big data ...

... ? This report will be of value to anyone involved emerging market development, particularly those with responsibilities in the following areas: Brand marketing and ... leader for a top five multinational company Marc Yates, director of emerging markets, Research Partnership Key Quotes: 'You know you have ...

Your step-by-step guide to adapting to real time change. Over the past decade, closed loop marketing (CLM) has been a buzzword in pharma marketing ... actionable by themselves. This is where most companies are stuck in the closed-loop marketing cycle.” Marc Valdiviezo, former director of multichannel marketing, Pfizer.

... introduction more effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C analyses the global HCV market players and ... results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections ...

... exposure? This timely new report will help anyone in the publications field discover ways to tackle new challenges and maximise new ... their experiences exclusively with FirstWord, including Gary Evoniuk, director of publication practices at GlaxoSmithKline, who talks candidly about GSK’s recent announcement ...

... with the greatest insight into how HCV clinical research will shape the future market. Key Benefits Hepatitis C: the race for the first interferon-free regimen examines the most prominent insights gained from the ... generation protease inhibitors Develop planning strategies based on insight from the field’s foremost KOLs Identify the unmet needs and opportunities for ...

... consumers themselves are able to express concerns online. The influence of social media on pharma marketing is such that even the largest and most ... looks at leading-edge activities such as data mining, investigates the future of mobile access, outlines legislative and regulatory efforts worldwide and offers ...

... help pharma companies answer these critical questions. REPORT OVERVIEW The Rise of Health Outcome Liaison Teams At last – a practical guide to building your ... HOL strategy. This comprehensive report explains what is driving the rise of HOLs globally, and provides detailed accounts of how major pharma ...

... will learn how to capitalise on those opportunities. Report Overview Advisory Committees and Speaker Bureaux – Ensuring Compliance With the Sunshine Act due to ... – detailing how a major pharma company manages its physician advisory boards and speaker programmes, how a major medical centre determines what ...

Following US approval of Aubagio (teriflunomide; Sanofi/Genzyme) for use in Relapsing Remitting Multiple Sclerosis patients (RRMS), FirstWord interviewed nearly 300 US-based neurologists within 24 hou...

Charting the Future Multiple Sclerosis Market LandscapeOver the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary d...

Changes in the healthcare landscape have put payers (public and private) under mounting pressure to reduce the cost of care, and given them much greater influence over market access to new medicines.I...

Analyse the latest global RA market players and products, and start mapping your future market parameters with Therapy Trends’ Consensus Outlook: Rheumatoid Arthritis, which includes the following com...

What the future holds Over the next few years, the global Rheumatoid Arthritis (RA) market is expected to grow from $16.5 billion in 2011 to $23.4 billion in 2016. This expansion of the market will b...

Therapy Trends KOL Insight: Rheumatoid Arthritis analyses the current and predicted key issues, clinical advances and late-stage pipeline products in the international and US RA markets. KOL Insight g...

Pharma is no stranger to the idea of nurturing and defending corporate reputations. But in this hyper-connected world, Likes and Tweets are replacing traditional authority sources and creating a compl...

... Dossier report: Pharma’s Future Role in CME. REPORT OVERVIEW Save time and effort by reviewing forecasts from 10 leading figures in the US and European CME fields ... role in future CME productions, or strategically direct these from the background. KEY REPORT FEATURES Recent and expected US and European CME regulations Latest pharma ...

... future of sampling is undoubtedly digital, but what are the best ways for brands to make this critical transition? Report Overview Sampling: A key business driver in a multi ... predictions for the future of product sampling. Sampling: A key business driver in a multi-channel environment is designed to help sales, marketing, and sampling logistics leaders learn best practices ...

... — Pharma sales force shape, size and structure — where next? — analyses the key issues influencing sales force objectives and structure; how some pharma companies have restructured their sales and marketing channels, and whether these changes have been successful or not. Report Overview Pharma sales force shape, size ...

In 2009, China’s government announced plans to invest RMB1.13 trillion ($180 billion) in expanding and improving healthcare provision, through significant healthcare reforms. These reforms have five k...

The real potential for orphan drug pharma marketing With drug pipelines moving from essential products to niche therapies, large pharma companies are increasingly attracted to the prospective high de...

... of this, and remain complacent about taking appropriate action. In New Product Penetration: Understanding & Accelerating New Product Uptake, FirstWord Dossier reviews the differences between complex pharmaceutical ... to new product penetration. The report also examines strategic tactics that big pharma are now using to improve their uptake curves. Report Overview New Product Penetration: Understanding ...

... , and a fresh perspective on stakeholders’ roles and responsibilities. Report Overview Managing Investigator-Initiated Research This comprehensive report brings together industry data, exclusive ... end-to-end IIR programme management Who Would Benefit From This Report? Managers and Executives with responsibilities in: Investigator-initiated research (IIR) programmes Branding ...

... milestone in AD treatment. Recent trends in the AD market also represent a clear shift in researchers’ approaches to detecting, treating and preventing AD. ‘Therapy Trends: Alzheimer’s Disease’ is compiled from exclusive ... ? What clinical research trends do KOLs predict for future AD therapies? The deliverables FirstWord’s ‘Therapy Trends: Alzheimer’s Disease’ is delivered to you in two complementary formats: Therapy Trends Intelligence Report: a concise ...

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse futu...

... launching their branded generic brands but I can't say for sure that success is guaranteed in South East Asia.” – Dr. Suchitra Kataria, former Head of Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer ...

... affiliate organisations. What strategies are emerging to tackle these challenges? Market Access: Communicating Value Stories to Payers shares up-to-the-minute insights and case studies from ... finding their way through this new environment. Report Overview Market Access: Communicating Value Stories to Payers provides unique, practical insights into how companies can ...